In November 2018, of the total 20 analysts covering Hologic (HOLX), ten analysts have given the stock a “buy” or higher rating, and ten analysts have given it a “hold” rating. The mean rating for Hologic stock is 2.3 with a target price of $45.09, implying an upside potential of 8.5% over Hologic’s closing price of $41.54 on November 21, 2018.
In comparison, for peers Abbott Laboratories (ABT), Boston Scientific (BSX), and Stryker (SYK), analysts have a mean rating of 1.8x, 1.52x, and 1.97x, respectively, and a target price of $78.94, $41.96, and $187.32, respectively. Hologic’s quick ratio stands at 1.0x. In comparison, the quick ratios of peers Abbott Laboratories (ABT), Boston Scientific (BSX), and Stryker (SYK) stand at 1.10x, 0.60x, and 1.20x, respectively.
Hologic’s long-term debt-to-equity ratio stands at 1.12x. In comparison, the long-term debt-to-equity ratios of peers Abbott Laboratories (ABT), Boston Scientific (BSX), and Stryker (SYK) stand at 0.63x, 0.58x, and 0.60x, respectively, which indicates Hologic has taken on a higher level of leverage as compared to its peers.
From $44.42 on January 8, 2018, Hologic stock slid to $36.43 on April 6, 2018. The stock rose to $42.92 on July 30, 2018, but fell to $37.90 on October 29, 2018, amid the broader market turmoil. Hologic stock has registered strong gains in November and is currently trading at $42 levels.
The enterprise value of Hologic is $14.12 billion, and its enterprise-value-to-revenue ratio is 4.39x. Hologic stock is currently trading at a forward price-to-earnings multiple of 15.85x.